Collaborating to Advance Our Programs and Technologies
At Sarepta Therapeutics we are committed to rapidly advancing our leading RNA-based technology platforms and pipeline. Strategically, we seek to build a diversified research and development portfolio balanced between select programs partnered with larger biopharmaceutical companies and Sarepta retained programs.
Our RNA-based technologies and PMO-X™, PMOplus™ and PPMO chemistries combine to make a versatile, collaboration-ready, therapeutics research and development platform with broad applicability. Our platform has demonstrated utility across multiple therapeutic categories, including the promise of potentially transformative, safe and effective treatment options for rare and infectious diseases.
In addition to offering our collaboration-ready RNA-based technology platform, we have multiple program opportunities available for partnering, including our clinical stage Duchenne muscular dystrophy program and several anti-infective and rare disease programs.
Beyond strategic partnerships with industry, Sarepta also maintains a continuing interest in establishing research-advancing collaborative agreements with select academic, governmental and non-governmental organizations.
For further information on partnering and collaboration with Sarepta, please send an email to Sarepta at firstname.lastname@example.org.